Literature DB >> 12606008

Evaluation of 11beta-HSD activities in vivo following oral administration of cortisol-13C4,2H1 to a human subject.

Yasuji Kasuya1, Akitomo Yokokawa, Shinji Takayama, Hiromi Shibasaki, Takashi Furuta.   

Abstract

This study is concerned with an oral administration of 5mg of [1,2,4,19-13C(4),11alpha-2H]cortisol (cortisol-13C(4),2H(1)) to a human subject to reliably evaluate the individual activities of two isozymes of 11beta-HSD. The use of a GC-MS method allowed the simultaneous measurement of the plasma concentrations of cortisol-13C(4),2H(1), cortisone-13C(4), and cortisol-13C(4) together with endogenous cortisol and cortisone. The loss of 11alpha-2H during the conversion of cortisol-13C(4),2H(1) to cortisone-13C(4) by 11beta-HSD2 and the regenerated cortisol-13C(4) from cortisone-13C(4) by 11beta-HSD1 provided a direct and accurate means of distinguishing the activities of the two isozymes. The kinetic analysis associated with the metabolism of orally administered cortisol-13C(4),2H(1) was of great importance in assessing the 11beta-HSD activities. From a viewpoint of the chemical stability and much less pronounced kinetic isotope effect of the 13C-label and the 2H-labeling in the 11alpha-position, cortisol-13C(4),2H(1) used in this study served as an appropriate tracer for elucidating the kinetics of the interconversion of cortisol to cortisone in man.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12606008     DOI: 10.1016/s0039-128x(02)00169-1

Source DB:  PubMed          Journal:  Steroids        ISSN: 0039-128X            Impact factor:   2.668


  2 in total

1.  Using a biokinetic model to quantify and optimize cortisol measurements for acute and chronic environmental stress exposure during pregnancy.

Authors:  Marissa N Smith; William C Griffith; Shirley A A Beresford; Melinda Vredevoogd; Eric M Vigoren; Elaine M Faustman
Journal:  J Expo Sci Environ Epidemiol       Date:  2013-12-04       Impact factor: 5.563

2.  Pharmacokinetic-pharmacodynamic studies of the 11β-hydroxysteroid dehydrogenase type 1 inhibitor MK-0916 in healthy subjects.

Authors:  D Hamish Wright; Julie A Stone; Tami M Crumley; Larissa Wenning; Wei Zheng; Kerri Yan; Amy Yifan Yang; Li Sun; Caroline Cilissen; Steven Ramael; Anne Hermanowski-Vosatka; Ronald B Langdon; Keith M Gottesdiener; John A Wagner; Eseng Lai
Journal:  Br J Clin Pharmacol       Date:  2013-12       Impact factor: 4.335

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.